Johnson and Johnson and AbbVie's Imbruvica receive FDA approval for treatment of rare blood tumorly lymphocyte lymphoma

recently, Johnson and Johnson(and AbbVie's Imbruvica) were awarded the U.SFoodMedicines(Supervisory Authority) for treatment of rare blood tumorly lymphocytic lymphomaimbruvicaImbruvica (Ilutini) is an efficient, highly selective small molecule BTK inhibitor, which is mainly combined in the BTK active site cys-481, inhibits tyr-223 itself phosphorylation, so that BTK can not be completely activated, affecting the normal function of its functionImbruvica was approved by China's C
FDA(approved for the market in August 2017 for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one treatment in the past, as well as patients with set cell lymphoma who have received at least one treatment in the past)studies have shown that errutinib has the effect of inhibiting the proliferation of malignant B cells and survival in the body, as well as in vitro cell migration and adhesion of substratesthe studythe approval was based on theDrug, which was presented earlier this month at the annual meeting of the American Society of Clinical OncologyThe experimental(the results show that Imbruvica and Rituxan can be used in conjunction with Rituxan to better alleviate the disease than using Rituxan alone.) Combined medication reduced a patient's risk of disease progression or death by 80 percent, and 82 percent of patients in the combined drug group showed no signs of cancer worsening during the 30-month treatment period, compared with 28 percent in the Rituxan alone the approval of the combined ambruvica and Rituxan drug will effectively reduce the need for chemotherapy, a common treatment option for the disease, accompanied by strong side effects